ecropolis

What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult | Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024 | Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study | The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger | Characterizing Long COVID in Children and Adolescents

Onward Virus Transmission after Measles Secondary Vaccination Failure | Single Monoclonal Antibodies Should Not be Used for COVID-19 Therapy: A Call for Antiviral Stewardship |
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort | Risk Factors for Long COVID Syndrome in Postmenopausal Women with Previously Reported Diagnosis of COVID-19 |
Long-COVID Symptom Monitoring: Insights from a Two-year Telemedicine Study

Long COVID Defined

Personal Protective Effect of Wearing Surgical Face Masks in Public Spaces on Self-reported Respiratory Symptoms in Adults |
Cohort Study of Cardiovascular Safety of Different COVID-19 Vaccination Doses among 46 million Adults in England | Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years | Incidence of Diabetes after SARS-CoV-2 Infection in England |
Post-COVID-19 Respiratory Sequelae Two Years after Hospitalization |
Incidence of Hearing Loss Following COVID-19 among Young Adults in South Korea | The Effect of Long-term COVID-19 Infection on Maternal and Fetal Complications

Insights from an N3C RECOVER EHR-based Cohort Study Characterizing SARS-CoV-2 Reinfections and Long COVID |
Cost-effectiveness of COVID Rapid Diagnostic Tests for Patients with Severe/Critical Illness in Low- and Middle-income Countries: A Modeling Study |
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine |
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19 | Tracking cognitive trajectories in older survivors of COVID-19 up to 2.5 years post-infection

Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 | Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for COVID-19 |
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity |
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19 |
Comparative Effectiveness of Combination Therapy with Nirmatrelvir–ritonavir and Remdesivir versus Monotherapy with Remdesivir | Postacute Sequelae of SARS-CoV-2 Infection |
The Efficacy of Antivirals, Corticosteroids, and mAbs as Acute COVID Treatments

Proton Pump Inhibitors and Risk of COVID-19 Infection in Children |
Long Covid The Answers

Effectiveness and Safety of Molnupiravir in the Intended-Use Population: An Observational Cohort Study | The Life-saving Benefit of Dexamethasone in Severe COVID-19 is Linked to a Reversal of Monocyte Dysregulation | EEG Signatures of Cognitive Decline after Mild SARS-CoV-2 Infection: An Age-dependent Study | Tissue-based T Cell Activation and Viral RNA Persist for Up to 2 Years after SARS-CoV-2 Infection